Mechanical Thrombectomy with Intravenous Thrombolysis versus Thrombolysis Alone for the Treatment of Stroke: A Systematic Review of Economic Evaluations

J Vasc Interv Radiol. 2023 Oct;34(10):1749-1759.e2. doi: 10.1016/j.jvir.2023.06.015. Epub 2023 Jun 17.

Abstract

Mechanical thrombectomy has revolutionized the management of stroke by improving the recanalization rates and reducing deleterious consequences. It is now the standard of care despite the high financial cost. A considerable number of studies have evaluated its cost effectiveness. Therefore, this study aimed to identify economic evaluations of mechanical thrombectomy with thrombolysis compared with thrombolysis alone to provide an update of existing evidence, focusing on the period after proof of effectiveness of mechanical thrombectomy. Twenty-one studies were included in the review: 18 were model-based economic evaluations to simulate long-term outcomes and costs, and 19 were conducted in high-income countries. Incremental cost-effectiveness ratios ranged from -$5,670 to $74,216 per quality-adjusted life year. Mechanical thrombectomy is cost-effective in high-income countries and in the populations selected for clinical trials. However, most of the studies used the same data. There is a lack of real-world and long-term data to analyze the cost effectiveness of mechanical thrombectomy in treating the global burden of stroke.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Administration, Intravenous
  • Brain Ischemia* / therapy
  • Cost-Benefit Analysis
  • Humans
  • Mechanical Thrombolysis*
  • Stroke* / drug therapy
  • Thrombectomy / adverse effects
  • Thrombolytic Therapy / adverse effects
  • Treatment Outcome